Seres Therapeutics (NASDAQ:MCRB) is set to announce its latest quarterly earnings on March 5, 2024, with analysts predicting an EPS of $-0.50.
In the previous quarter, the company exceeded expectations by $0.13, leading to a 39.43% surge in share price the following day.
Despite shares currently trading at $1.23 as of March 01 and a 52-week decline of 78.52%, long-term investors are understandably worried about the negative returns.
Investors are eagerly awaiting to see if Seres Therapeutics will not only beat the projected EPS but also offer positive guidance for future growth, as this could have a significant impact on stock prices.
MCRB Stock Plummets 6.91% on March 4, 2024, Trading Near 52-Week Low
On March 4, 2024, MCRB stock experienced a significant drop in price, trading near the bottom of its 52-week range and below its 200-day simple moving average. The stock opened at $1.23, inline with its previous close, but quickly saw a decrease of $0.08, representing a 6.91% drop since the market last closed.
MCRB Stock Plummets: Analyzing the Significant Decline in Financial Performance
On March 4, 2024, MCRB stock experienced a significant decline in its financial performance compared to the previous year and quarter. According to data from CNN Money, the company reported total revenue of $7.13 million over the past year, which represents a 95.08% decrease from the previous year. In the third quarter, total revenue further decreased to $310,000, marking a staggering 99.75% decrease from the previous quarter.
Similarly, MCRB reported a net income of -$250.16 million over the past year, reflecting a 281.46% decrease from the previous year. In the third quarter, net income further declined to -$47.85 million, representing a 202.8% decrease from the previous quarter.
Earnings per share (EPS) also saw a significant decrease for MCRB. The company reported an EPS of -$2.31 over the past year, which is a 223.68% decrease from the previous year. In the third quarter, EPS decreased to -$0.37, marking a 204.04% decrease from the previous quarter.
Overall, these financial metrics indicate a challenging period for MCRB, with significant declines in total revenue, net income, and EPS. Investors and analysts may need to closely monitor the company’s financial performance and strategy moving forward to assess its ability to recover from these declines and drive future growth.
